Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad Genetics Inc.

www.myriad.com

Latest From Myriad Genetics Inc.

ASCO 2017: Myriad's MyRisk; Nanobiotix' NBTXR3; Chronix' CNI Test; Sirtex SIR-Spheres; ANGLE’s Parsortix CTC Harvester

Over 30,000 oncologists and other health professionals attended the 2017 American Society of Clinical Oncology annual meeting in Chicago, June 2-6. This year's meeting included several presentations on emerging cancer diagnostic and device treatment strategies, including genetic tests, liquid biopsy systems, radioenhancers, and microspheres intended to improve chemotherapy outcomes.

Cancer In Vitro Diagnostics

Myriad's BRACAnalysis CDx Proves Mettle In Patient Selection For AstraZeneca's Olaparib Therapy

Patients with HER2- metastatic breast cancer and who were tested positive for BRCA1/2 mutations with Myriad's BRACAnalysis CDx companion diagnostic showed they benefitted more from AstraZeneca's Lynparza (olaparib) than standard chemotherapy, according to results from a Phase III trial.

Cancer In Vitro Diagnostics

Device Debuts: Tryton, Myriad Genetics, Integra Lifesciences, Acelity, And Toyota

This edition of device debuts highlights a wide variety of innovative devices introduced into commercial markets since the beginning of March, including a new stent for side-branch coronary interventions, an assay that identifies which breast-cancer patients do not need chemotherapy, a full ankle prosthesis, improvements to a negative-pressure wound therapy system, and a robotic system that helps paralyzed people learn to walk again.

Research & Development Clinical Trials

Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Myriad Genetics Inc.
  • Senior Management
  • Mark C Capone, Pres. & CEO
    R. Bryan Riggsbee, EVP, CFO & Treasurer
    Jerry H Lanchbury, PhD, CSO
  • Contact Info
  • Myriad Genetics Inc.
    Phone: (801) 584-3600
    320 Wakara Way
    Salt Lake City, UT 84108
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register